Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)-Reference-Cited by-同舟云学术

Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)

Published:2020-08 Issue: Volume:149 Page:8-13
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Alayed Yasir,Quon Harvey,Ong Aldrich^ORCID,Cheung Patrick,Chu William,Chung Hans,Vesprini Danny^ORCID,Chowdhury Amit,Panjwani Dilip,Pang Geordi,Korol Renee,Davidson Melanie,Ravi Ananth,McCurdy Boyd,Zhang Liying,Mamedov Alexandre^ORCID,Deabreu Andrea,Loblaw Andrew^ORCID

Funder

Prostate Cancer Canada

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology

Reference25 articles.

1. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013;Amin;Appl Health Econ Health Policy,2014

2. Stereotactic body radiotherapy for prostate cancer;Henderson;Clin Oncol,2015

3. Dose escalation for prostate stereotactic ablative radiotherapy (SABR): late outcomes from two prospective clinical trials;Alayed;Radiother Oncol,2018

4. Stereotactic body radiotherapy for low-risk prostate cancer: A ten-year analysis;Katz;Cureus,2017

5. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials;King;Radiother Oncol,2013

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial;Radiation Oncology;2024-05-03

2. Long-Term Outcomes Following Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy in High-Risk Prostate Cancer: Update From the FASTR/FASTR-2 Trials;Practical Radiation Oncology;2024-01

3. Simplifying the Biology: Stem, Stroma and Beyond;Hypofractionated and Stereotactic Radiation Therapy;2024

4. To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer;International Journal of Radiation Oncology*Biology*Physics;2023-12

5. The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer—Quo Vadimus?;World Journal of Urology;2023-11-03